Claims
- 1. A transgenic mouse whose genome comprises a homozygous disruption of an endogenous ACC2 gene for the acetyl-CoA carboxylase-2 isoform of acetyl-CoA carboxylase, wherein said disruption inactivates said gene and wherein said mouse does not produce any functional acetyl-CoA carboxylase-2.
- 2. The mouse of claim 1 wherein one or more exons of said ACC2 gene has been deleted.
- 3. The mouse of claim 2, wherein said exons have been replaced with heterologous DNA sequences.
- 4. The mouse of claim 3, wherein said heterologous DNA sequences comprise an HPRT expression cassette.
- 5. The mouse of claim 4, wherein an exon encoding a biotin binding motif of ACC2 is replaced with an HPRT expression cassette.
- 6. The mouse of claim 1, wherein said mouse exhibits a phenotype comprising a metabolic reduction in malonyl-CoA production in skeletal muscle and heart.
- 7. The mouse of claim 6, further comprising a phenotype of unrestricted fat oxidation and reduced fat accumulation in the liver and fat storage cells.
- 8. The mouse of claim 7, further comprising a phenotype of consuming more calories than a wild type mouse yet accumulating less fat than a wild type mouse.
- 9. A cell line derived from the transgenic mouse of claim 1.
- 10. The cell line of claim 9, wherein said cell line is derived from cells selected from the group consisting of muscle cells, heart cells, adipose cells, and liver cells.
FEDERAL FUNDING LEGEND
This invention was produced in part using funds from the Federal government under N.I.H. G.M. 19091. Accordingly, the Federal government has certain rights in this invention.
Non-Patent Literature Citations (2)
Entry |
Moreadith et al. Gene targeting in embryonic stem cells: the new physiology and metabolism, Journal of Molecular Medicine, 1997, vol. 75, pp. 208-216.* |
Moens et al. Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus, Development, 1993, vol. 119, pp. 485-499. |